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The original Society for Cardiovascular Angiography and
Intervention (SCAI) SHOCK Classification statement was
presented at the Houston Shock Symposium in 2019, shortly
before its official publication.1 This generated substantial
discussion among the conference attendees, and it was
immediately apparent that validation studies were needed to
demonstrate the utility of this new staging system for defining
the severity and prognosis of cardiogenic shock (CS).
Together with several other attendees who were coauthors on
the SCAI SHOCK Classification statement, we started
planning a retrospective analysis to explore how to assign the
SCAI SHOCK Classification using clinical data objectively.
To achieve this, we met as a group to develop a consensus
definition for each SCAI Shock stage using clinical,
laboratory, and vital sign data available in the Mayo Clinic
cardiac intensive care unit (CICU) database. The SCAI Shock
Classification provided surprisingly robust mortality risk
stratification in this population of 10,000 CICU patients with
or at risk for CS, even after adjusting for established markers
of illness severity and other prognostic variables.2 The results
held true in patients with acute coronary syndromes or heart
failure, and cardiac arrest conferred incremental risk at each
SCAI SHOCK stage consistent with the proposed “A”
modifier from the SCAI SHOCK Classification statement.3
The manuscript was published later that year, quickly
followed by several additional publications confirming and
expanding upon these findings. These studies uniformly
demonstrated that the SCAI SHOCK Classification provided
incremental mortality risk stratification for patients across the
spectrum of shock severity, regardless of the population
studied.4-7 Furthermore, additional potential risk modifiers
emerged that could provide a graded prognostic assessment at

each SCAI SHOCK stage.8 This led to the development and
publication of a revised SCAI SHOCK Classification earlier
this year, which we were both fortunate to participate in
writing.9 This new statement highlighted the validity of the
original SCAI SHOCK Classification and provided subtle
modifications and clarifications while, by and large,
maintaining the same structure. Based on studies published
since the original SCAI SHOCK Classification statement, age
was added as an established risk modifier, and the arrest
modifier was changed to reflect only those post-arrest patients
with possible neurologic compromise (i.e., coma).8-11
The revised SCAI SHOCK Classification statement
underscores the practical application of the SCAI SHOCK
Classification for mortality risk stratification, yet several
unanswered questions remain. Chief among these is the need
to leverage the SCAI SHOCK Classification to provide risktailored treatment strategies for individual patients with CS.
To date, no randomized clinical trial has demonstrated clear
evidence of heterogeneity of response to treatment in CS
patients according to baseline mortality risk. To some extent,
this may result from the inclusion of both shock-related and
non-modifiable risk factors in established mortality prediction
scores.12, 13 However, the SCAI SHOCK Classification could
provide a unique opportunity to provide individualized
management of CS patients by matching the degree of support
to the severity of CS. While this approach remains speculative,
it seems logical to evaluate this strategy objectively.
Our first attempt to address this question utilized the Mayo
Clinic CICU database. It examined the propensity-adjusted
association between intra-aortic balloon pump (IABP) use and
mortality across the SCAI SHOCK stages in patients with CS
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from diverse etiologies.14 This analysis suggested an
association between the use of the IABP and lower mortality,
an effect that may have been more prominent at lower shock
severity. This finding was conceptually appealing considering
the modest hemodynamic support provided by the IABP,
particularly when compared to the high severity of CS
observed in randomized clinical trials evaluating this therapy.
These findings are speculative based on the observational
nature of this analysis but stress the potential to utilize the
SCAI SHOCK Classification to tailor hemodynamic support.
We have proposed an incremental approach to hemodynamic
support according to the SCAI SHOCK Classification,
recognizing that prior studies have not demonstrated
improvements in outcomes when temporary mechanical
circulatory support (MCS) devices are used uniformly.15, 16
The impetus to use the SCAI SHOCK Classification to guide
therapy is supported by the surprisingly minimal differences
in most standard hemodynamic measurements across the
SCAI SHOCK stages despite dramatic differences in the
severity of shock and critical illness.4, 7 CS is too
heterogeneous a disease to realistically create a formulaic onesize-fits-all care strategy that applies to all patients with CS,
but a structured approach to evaluation and management
tailored to shock severity is feasible.16
An ideal opportunity to utilize the SCAI SHOCK
Classification to facilitate clinical care comes in the context of
the shock team. Despite different approaches utilized at
various institutions, establishing a shock team has improved
outcomes for patients with CS.17-19 In addition to providing a
standardized multidisciplinary evaluation for patients with
CS, the shock team can facilitate consistent care tailored to
each patient’s needs. By assigning the SCAI SHOCK stage in
an agreed-upon manner, the shock team members can
communicate clearly and provide a structured approach to
initiating and escalating temporary MCS that is more likely to
yield benefits than use without a formal approach. Each
institution can develop a consensus approach to assigning the
SCAI SHOCK Classification to help specify which patients
will be selected for specific temporary MCS devices, enabling
streamlined care congruent with institutional best practices.
While the shock team can come to these same conclusions ad
hoc for each patient, having an established algorithm ensures
that the team's composition does not impact the quality of care.
This strategy allows each institution to define the preferred
approach to CS management in a manner that can be used to
expand beyond a single facility to build a hub-and-spoke CS
care network.20 Unfortunately, examining the effects of such
an approach in a classic randomized clinical trial may not be
feasible. However, an implementation science approach (eg,
stepped-wedge pragmatic trial) could be effective.
Nonetheless, determining which aspects of shock team
management are associated with improved outcomes can be
evaluated objectively to develop a set of core best practices for
shock team performance.
Implementation of the SCAI SHOCK Classification can
take many incarnations. Simplified approaches to the SCAI
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SHOCK Classification can be taught quickly and easily to
providers of all training and experience, and clinician
assignment of the SCAI SHOCK stage performs as well as a
more complex data-driven algorithm for risk stratification.4
Alternatively, the electronic medical record can be utilized to
determine the SCAI SHOCK stage automatically using
laboratory and vital sign data. The former approach in the
prehospital and emergency department setting might enable
better triage decisions and early management for patients with
CS. The latter approach can identify hospitalized patients with
established or impending CS to facilitate rapid recognition and
stabilization; we are currently exploring this approach at the
Mayo Clinic. Either of these assessments can be performed
serially over time to assess patient trajectory, with important
prognostic and treatment implications. A persistently high or
rising SCAI SHOCK stage portends a poor outcome and
should prompt consideration of escalation in terms of medical
therapy and MCS.4, 5
It is essential to recognize that decision-making for
patients with CS is substantially more complicated than
matching the flow provided by a temporary MCS device to the
hemodynamics or even the SCAI SHOCK stage. This was
delineated in the revised SCAI SHOCK Classification
statement, which identified three core constructs involved in
prognostication and decision-making for patients with CS:
shock severity, phenotype, and risk modifiers.9 The premise is
that at each level of shock severity, patients may display
different patterns of cardiac, hemodynamic, and other clinical
features that portend different levels of risk and necessitate
different approaches to hemodynamic support, including
temporary MCS. Additionally, a host of non-modifiable risk
factors for mortality (including brain injury from cardiac arrest
and age, among others) that are not directly related to shock
severity can further impact prognosis and determine
candidacy for different potential therapies. Integrating all
these components is necessary for risk stratification and, more
importantly, developing a management strategy for each CS
patient in a manner analogous to the TNM staging system used
for malignancy or the MOGE(S) or HLM classification
systems proposed for heart failure.21-23 In this way, a patient
with mild shock may have a poor outcome due to ineligibility
for temporary MCS in the setting of advanced age, extensive
comorbidities, and severe anoxic brain injury after cardiac
arrest. A different patient with severe shock may have a more
favorable prognosis in the absence of these complicating
factors, allowing the patient to be a candidate for advanced
temporary MCS and cardiac replacement therapy if needed.
These complex and nuanced decisions are difficult to
operationalize, but this paradigm can be used to guide shock
team discussions. The essential component to recognize is that
many of the prognostically important variables in CS patients
are not related to shock severity per se and may not be
improved using temporary MCS, resulting in poor outcomes.
Despite the ongoing trials, there will continue to be
unanswered questions.24, 25 There is a significant role for
multicenter registries such as the Cardiogenic Shock Working
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Group and VANQUISH registries, as well as the planned
American Heart Association Cardiogenic Shock Registry.7, 26
The VANQUISH registry will record the team-assessed SCAI
SHOCK Stage at baseline and two days, as well as collect
quality of life data and biomarkers serially throughout the
course of the patient with cardiogenic shock.26 Additionally,
this registry includes all cases seen by the local shock teams,
whether the patient received MCS or not, to reduce selection
bias. Prospective enrollment of patients in these multicenter
registries with mature shock teams will enable greater insights
to be gleaned, ideally including linking underlying biomarker
patterns and clinical phenotypes with outcomes and treatment
responses.16
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[7]

[8]

[9]

Beyond the potential utility of the SCAI SHOCK
Classification for improving patient care, our story should be
particularly instructive to early career researchers. The
relationships with other interested experts that are developed
at small but focused meetings, such as the Houston Shock
Symposium, are invaluable, and the experience is hard to
replicate at larger and less intimate meetings. The impact of
the research collaboration and career mentorship that grows
from these chance meetings cannot be overstated. We are both [10]
grateful to have met at the Houston Shock Symposium in
2019. Due to this chance meeting, we have published a dozen
(and counting) collaborative manuscripts together. Even more
importantly, we believe that together, we are moving the [11]
science of CS research forward and hope that lives will be
saved by a better understanding of this disease that will
translate to improved care strategies.
[12]
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